Merck & Co doubles up on Ablynx research deal


Cut-down antibody drug developer Ablynx has agreed a second R&D partnership with US Pharma firm Merck & Co. Ablynx will receive €20 million (£17 million) up front, plus up to €10.7 million in research funding over three years. On top of that, milestone payments for any products that emerge from the collaboration could net the Belgian biotech up to €1.7 billion plus royalties.

This collaboration will focus on nanobodies (antibody fragments) directed against cancer, and builds on Merck’s previous collaboration with Ablynx for nanobodies that target voltage-gated ion channels. Ablynx also recently joined forces with Abbvie to develop nanobodies for treating rheumatoid arthritis and systemic lupus erythematosus.


Related Content

Merck & Co $460m ion channel deal

2 October 2012 Business

news image

Deal with Ablynx relates to antibody fragments

Business roundup

27 April 2011 Business

news image

Industry news, May 2011

Most Read

Lawrencium experiment could shake up periodic table

9 April 2015 Research

news image

Measurement of first ionisation energy confirms electronic configuration but opens up an important debate

Silicon chip spots dangerous pathogens in human blood

10 April 2015 Research

news image

Silicon wafer doped with silver nanoparticles can rapidly identify E. coli in blood

Most Commented

Women twice as likely to be hired for academic posts as men

17 April 2015 News and Analysis

news image

Experiment shows that faculty staff are more likely to pick women for job roles based on hypothetical CVs

Lawrencium experiment could shake up periodic table

9 April 2015 Research

news image

Measurement of first ionisation energy confirms electronic configuration but opens up an important debate